piperacillin-tazobactam + glycopeptide

**Piperacillin-tazobactam + glycopeptide** is a combination antimicrobial regimen commonly used as broad-spectrum empirical therapy for severe infections, especially in febrile neutropenic patients, hospital-acquired pneumonia, and other serious hospital-acquired infections. **Piperacillin** is a ureidopenicillin β-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while **tazobactam** inhibits bacterial β-lactamase enzymes, protecting piperacillin from hydrolysis[2][3]. *Glycopeptide* antibiotics (most often vancomycin or teicoplanin) act by inhibiting cell wall synthesis through binding to the D-Ala-D-Ala terminus of cell wall precursor units. This combination thus covers a wide range of Gram-negative organisms (including Pseudomonas) and Gram-positive organisms (including coverage for drug-resistant species like MRSA when using glycopeptides)[2]. The regimen is generally administered intravenously and is a recommended empirical therapy in cases of suspected multidrug-resistant bacterial infections or in immunocompromised populations[1][2].

Brand names

Zosyn + vancomycin

Other names

piperacillin/tazobactam + glycopeptidepiperacillin-tazobactam + vancomycinpip/taz + glycopeptide